MUMC+
Dr. T. van Nijnatten, Nucleair radioloog MUMC+
Aike Bruijsten
MD, PhD candidate Maastricht University
Department of Radiology and Surgery
GROW School for Oncology & Reproduction
KWF
This research consists of a retrospective and a prospective cohort of HER2+ invasive breast cancer patients with a DCIS component. Both in the retrospective and the prospective cohort, imaging and histopathology will be collected and centrally reviewed. It aims to improve surgical decision-making by predicting and detecting the complete response of DCIS in these HER2+ IBC patients.
To determine if it is possible to accurately predict and detect a complete response of the DCIS component accompanying HER2+ IBC using a prediction model based on the retrospective selected histopathologic and imaging findings
Inclusion criteria
All women age 18 years or older with HER2+ IBC with a DCIS component in the biopsy
Exclusion criteria
Treated with/scheduled for neoadjuvant treatment other than chemotherapy with dual anti-HER2 therapy.
